Insmed (NASDAQ:INSM) Stock Rating Lowered by BidaskClub

BidaskClub downgraded shares of Insmed (NASDAQ:INSM) from a buy rating to a hold rating in a research note released on Wednesday, May 22nd, BidAskClub reports.

INSM has been the topic of a number of other reports. ValuEngine downgraded shares of Insmed from a strong-buy rating to a buy rating in a research note on Tuesday, February 5th. Zacks Investment Research raised shares of Insmed from a hold rating to a buy rating and set a $28.00 target price on the stock in a research note on Tuesday, January 22nd. HC Wainwright reaffirmed a buy rating and set a $52.00 target price (up from $43.00) on shares of Insmed in a research note on Tuesday, April 9th. Canaccord Genuity set a $44.00 target price on shares of Insmed and gave the stock a buy rating in a research note on Friday, March 8th. Finally, JMP Securities raised shares of Insmed from a market perform rating to an outperform rating and set a $40.00 target price on the stock in a research note on Friday, February 15th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Insmed has a consensus rating of Buy and a consensus price target of $37.88.

INSM stock traded down $0.91 during midday trading on Wednesday, hitting $23.80. 691,100 shares of the stock traded hands, compared to its average volume of 968,561. Insmed has a 1-year low of $11.31 and a 1-year high of $33.13. The firm has a market cap of $1.82 billion, a PE ratio of -5.71 and a beta of 3.04. The company has a debt-to-equity ratio of 2.48, a quick ratio of 4.69 and a current ratio of 4.82.

Insmed (NASDAQ:INSM) last announced its earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.94) by ($0.02). The firm had revenue of $21.90 million for the quarter, compared to analyst estimates of $19.61 million. Research analysts predict that Insmed will post -3.7 earnings per share for the current fiscal year.

In related news, Director Donald J. Hayden, Jr. sold 6,286 shares of Insmed stock in a transaction that occurred on Tuesday, April 9th. The shares were sold at an average price of $32.99, for a total value of $207,375.14. Following the completion of the transaction, the director now owns 68,483 shares in the company, valued at $2,259,254.17. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 12,000 shares of Insmed stock in a transaction that occurred on Thursday, June 6th. The shares were sold at an average price of $23.24, for a total transaction of $278,880.00. Following the completion of the transaction, the insider now owns 36,350 shares of the company’s stock, valued at approximately $844,774. The disclosure for this sale can be found here. 4.95% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of INSM. Vivo Capital LLC acquired a new position in Insmed during the 1st quarter worth approximately $34,020,000. Norges Bank acquired a new position in Insmed during the 4th quarter worth approximately $9,955,000. Dimensional Fund Advisors LP lifted its position in shares of Insmed by 260.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 782,614 shares of the biopharmaceutical company’s stock worth $10,268,000 after buying an additional 565,297 shares during the last quarter. Federated Investors Inc. PA purchased a new stake in shares of Insmed during the 1st quarter worth approximately $9,825,000. Finally, Emerald Mutual Fund Advisers Trust lifted its position in shares of Insmed by 64.1% during the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 841,119 shares of the biopharmaceutical company’s stock worth $24,451,000 after buying an additional 328,472 shares during the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Featured Story: Special Dividends

Analyst Recommendations for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply